Multiomic Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease
Nov
08
2025
Convention Center: Ballroom B, Level 3
11:00 AM
- 12:30 PM
World Class Speakers
Description
Presenters review how genomic, trasncriptomic, and other omic technologies can help us understand the causes and inform treatments for MASLD. Experts elaborate on integrative multiomic analyses, genetic subtyping and risk stratification, phenotypic clustering, microbiome analyses, and metabolic and genetic metabolomic profiles as they relate to MASLD.Journey Maps
Presentations
11:00 AM
- 11:15 AM
Apr
29
2026
Washington, D.C.
Integrative Multiomic Analyses of Metabolic Dysfunction-Associated Steatotic Liver Disease
Xinshou Ouyang, PhD
, Presenter
MASLD
11:15 AM
- 11:30 AM
Apr
29
2026
Washington, D.C.
Genetic Subtyping and Risk Stratification for Metabolic Dysfunction-Associated Steatotic Liver Disease
Elizabeth Speliotes, MD, MPH, PhD, FAASLD
, Presenter
MASLD
11:30 AM
- 11:45 AM
Apr
29
2026
Washington, D.C.
Microbiome Analyses of Metabolic Dysfunction-Associated Steatotic Liver Disease
Silvia Sookoian, MD, PhD, FAASLD
, Presenter
MASLD
11:45 AM
- 12:00 PM
Apr
29
2026
Washington, D.C.
Metabolic and Genetic Metabolomic Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease
Panu K Luukkonen, MD, PhD
, Presenter
MASLD
Objectives
- Explain how genomics can inform the etiology, risk stratification, and treatment of MASLD.
- Describe how transcriptomics can inform the etiology, risk stratification, and treatment of MASLD.
- Recognize how metabolomics and microbiomics can inform the etiology, risk stratification, and treatment of MASLD.
Chair
Elizabeth Speliotes, MD, MPH, PhD, FAASLD
University of Michigan Medical Center